{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T03:31:42Z","timestamp":1783049502307,"version":"3.54.6"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872515, 82073423, and 82003327"],"award-info":[{"award-number":["81872515, 82073423, and 82003327"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010261","name":"Fok Ying Tung Education Foundation","doi-asserted-by":"publisher","award":["161038"],"award-info":[{"award-number":["161038"]}],"id":[{"id":"10.13039\/501100010261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>CLOVES syndrome (OMIM#\u00a0612918) is a rare overgrowth disorder resulted from mosaic gain-of-function mutations in the<jats:italic>PIK3CA<\/jats:italic>gene. All the reported CLOVES-associated<jats:italic>PIK3CA<\/jats:italic>mutations are missense mutations affecting certain residues. We aim to investigate underlying mutation and its pathogenicity in a patient with CLOVES syndrome and to evaluate the inhibitory effects of the PI3K\/AKT\/mTOR pathway inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We performed whole-exome sequencing (WES) and Sanger sequencing to detect underlying somatic mutations in the skin lesion of the patient. Quantitative real-time PCR (qRT-PCR) was employed to evaluate the mRNA abundance of<jats:italic>PIK3CA<\/jats:italic>in the patient\u2019s skin lesion. AKT phosphorylation level assessed by immunoblotting of lysates from transiently transfected cells was performed to evaluate the<jats:italic>PIK3CA<\/jats:italic>mutations and inhibitory effects of PI3K\/AKT\/mTOR pathway inhibitors. A somatic frameshift mutation c.3206_3207insG (p.X1069Trpfs*4) in<jats:italic>PIK3CA<\/jats:italic>was identified in the genomic DNA extracted from the vascular malformation sample of the patient. This mutation affects the canonical stop codon of<jats:italic>PIK3CA<\/jats:italic>(NM_006218.4) and is predicted to produce a prolonged protein with four additional residues. qRT-PCR demonstrated that the mRNA expression levels of the patient\u2019s affected skin tissue were comparable compared to the normal control. In vitro studies revealed that p.X1069Trpfs*4 mutant exhibited increased AKT phosphorylation significantly to that of the wildtype, which could be inhibited by PI3K\/AKT\/mTOR pathway inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We have identified the first frameshift mutation in<jats:italic>PIK3CA<\/jats:italic>that causes CLOVES syndrome, which was confirmed to overactive PI3K\/AKT\/mTOR pathway by transient transfection assays. We also provided more evidence of ARQ092 to be a potential therapeutic option for PROS in vitro.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s41065-021-00184-y","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T16:02:55Z","timestamp":1622563375000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K\/AKT\/mTOR pathway"],"prefix":"10.1186","volume":"158","author":[{"given":"Wei","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimiao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"issue":"8","key":"184_CR1","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nrg1879","volume":"7","author":"JA Engelman","year":"2006","unstructured":"Engelman JA, Luo J, Cantley LC, et al. The evolution of phosphatidylinositol. 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7(8):606\u201319.","journal-title":"Nat Rev Genet"},{"issue":"8","key":"184_CR2","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrd2926","volume":"8","author":"P Liu","year":"2009","unstructured":"Liu P, Cheng H, Roberts, et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8(8):627\u201344.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"184_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrm2882","volume":"11","author":"Vanhaesebroeck","year":"2010","unstructured":"Vanhaesebroeck, Guillermet-Guibert, Graupera, et al. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11(5):329\u201341.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"184_CR4","unstructured":"International Society for the Study of Vascular Anomalies. Classification for vascular anomalies. ISSVA; 2014."},{"issue":"2","key":"184_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/ajmg.a.36836","volume":"0","author":"KM Keppler-Noreuil","year":"2015","unstructured":"Keppler-Noreuil KM, Rios JJ, et al. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet A. 2015;0(2):287\u201395.","journal-title":"Am J Med Genet A"},{"issue":"6","key":"184_CR6","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ajhg.2015.11.011","volume":"97","author":"N Limaye","year":"2015","unstructured":"Limaye N, Kangas J, Mendola A, et al. Somatic activating PIK3CA mutations cause venous malformation. Am J Hum Genet. 2015;97(6):914\u201321.","journal-title":"Am J Hum Genet"},{"issue":"8","key":"184_CR7","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman JA. Targeting PI3K signaling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550\u201362.","journal-title":"Nat Rev Cancer"},{"issue":"24","key":"184_CR8","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1002\/ajmg.a.32023","volume":"143A","author":"Sapp","year":"2007","unstructured":"Sapp, Turner, van de Kamp, van Dijk, et al. Newly delineated syndrome of congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE syndrome) in seven patients. Am J Med Genet. 2007;143A(24):2944\u201358.","journal-title":"Am J Med Genet"},{"issue":"1","key":"184_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MCD.0b013e328317a716","volume":"18","author":"AI Alomari","year":"2009","unstructured":"Alomari AI. Characterization of a distinct syndrome that associates complex truncal overgrowth, vascular, and acral anomalies: a descriptive study of 18 cases of CLOVES syndrome. Clin Dysmorphol. 2009;18(1):1\u20137.","journal-title":"Clin Dysmorphol"},{"issue":"2","key":"184_CR10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/ajmg.a.32632","volume":"149A","author":"AI Alomari","year":"2009","unstructured":"Alomari AI. CLOVE(S) syndrome: expanding the acronym. Am J Med Genet. 2009;149A(2):294\u20135.","journal-title":"Am J Med Genet"},{"issue":"2","key":"184_CR11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jtcvs.2010.04.023","volume":"140","author":"Alomari","year":"2010","unstructured":"Alomari, Burrows, Lee EY, et al. CLOVES syndrome with thoracic and central phlebectasia: increased risk of pulmonary embolism. J Thorac Cardiovasc Surg. 2010;140(2):459\u201363.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"10","key":"184_CR12","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.3174\/ajnr.A2349","volume":"32","author":"Alomari","year":"2011","unstructured":"Alomari, Chaudry, Rodesch, et al. Complex spinal-paraspinal fast-flow lesions in CLOVES syndrome: analysis of clinical and imaging findings in 6 patients. AJNR Am J Neuroradiol. 2011;32(10):1812\u20137.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"6","key":"184_CR13","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.ajhg.2012.05.006","volume":"90","author":"KC Kurek","year":"2012","unstructured":"Kurek KC, Luks VL, Ayturk UM. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am J Hum Genet. 2012;90(6):1108\u201315.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"184_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1078-0432.CCR-16-0134","volume":"23","author":"IA Mayer","year":"2017","unstructured":"Mayer IA, Abramson VG, Formisano L, et al. A phase Ib study of alpelisib (BYL719), a PI3K\u03b1-specific inhibitor, with letrozole in ER+\/HER2-negative metastatic breast cancer. Clin Cancer Res. 2017;23(1):26\u201334.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"184_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10048-018-0540-1","volume":"19","author":"C Ranieri","year":"2018","unstructured":"Ranieri C, Di Tommaso S, Loconte DC, et al. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS). Neurogenetics. 2018;19(2):77\u201391.","journal-title":"Neurogenetics"},{"issue":"7711","key":"184_CR16","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41586-018-0217-9","volume":"558","author":"Q Venot","year":"2018","unstructured":"Venot Q, Blanc T, Rabia SH, et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature. 2018;558(7711):540\u20136.","journal-title":"Nature"},{"issue":"10","key":"184_CR17","first-page":"140479","volume":"10","author":"Y Yu","year":"2015","unstructured":"Yu Y, Eathiraj S, Meade J, et al. Targeting AKT1-E17K and the PI3K\/AKT pathway with an allosteric AKT inhibitor, ARQ 092. PLoS One. 2015;10(10):140479.","journal-title":"PLoS One"},{"issue":"6","key":"184_CR18","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/mc.20628","volume":"49","author":"X Chen","year":"2010","unstructured":"Chen X, Liu F, Wang Z, et al. Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways. Mol Carcinog. 2010;49(6):603\u201310.","journal-title":"Mol Carcinog"},{"key":"184_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ctrv.2017.07.005","volume":"59","author":"F Janku","year":"2017","unstructured":"Janku F. Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: from laboratory to patients. Cancer Treat. 2017;59:93\u2013101.","journal-title":"Cancer Treat"},{"key":"184_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.semcancer.2017.04.014","volume":"48","author":"PA Gagliardi","year":"2018","unstructured":"Gagliardi PA, Puliafito A, Primo L, et al. PDK1: at the crossroad of cancer signaling pathways. Semin Cancer Biol. 2018;48:27\u201335.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"184_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13046-018-0773-8","volume":"37","author":"X Tian","year":"2018","unstructured":"Tian X, Guan W, Zhang L, et al. Physical interaction of STAT1 isoforms with TGF-beta receptors leads to functional crosstalk between two signaling pathways in epithelial ovarian cancer. J Exp Clin Cancer Res. 2018;37(1):103.","journal-title":"J Exp Clin Cancer Res"},{"issue":"62","key":"184_CR22","doi-asserted-by":"publisher","first-page":"31971","DOI":"10.18632\/oncotarget.25865","volume":"9","author":"H Kaida","year":"2018","unstructured":"Kaida H, Azuma K, Kawahara A, et al. The assessment of correlation and prognosis among 18F-FDG uptake parameters, Glut1, pStat1 and pStat3 in surgically resected non-small cell lung cancer patients. Oncotarget. 2018;9(62):31971\u201384.","journal-title":"Oncotarget"},{"issue":"3","key":"184_CR23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.ajhg.2019.01.015","volume":"104","author":"M Kim","year":"2019","unstructured":"Kim M, Julie C, Marjorie J, et al. Pharmacodynamic study of Miransertib in Individuals with Proteus syndrome. Am J Hum Genet. 2019;104(3):484\u201391.","journal-title":"Am J Hum Genet"},{"issue":"7","key":"184_CR24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa1104017","volume":"365","author":"Lindhurst","year":"2011","unstructured":"Lindhurst, Sapp, Teer, et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med. 2011;365(7):611\u20139.","journal-title":"N Engl J Med"},{"key":"184_CR25","doi-asserted-by":"crossref","unstructured":"Lindhurst MJ, Yourick MR, Yu Y, et al. Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome. Sci Rep. 2015;5:17162.","DOI":"10.1038\/srep17162"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-021-00184-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-021-00184-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-021-00184-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T23:43:56Z","timestamp":1725147836000},"score":1,"resource":{"primary":{"URL":"https:\/\/hereditasjournal.biomedcentral.com\/articles\/10.1186\/s41065-021-00184-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["184"],"URL":"https:\/\/doi.org\/10.1186\/s41065-021-00184-y","relation":{},"ISSN":["1601-5223"],"issn-type":[{"value":"1601-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]},"assertion":[{"value":"2 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained in adherence to the Declaration of Helsinki Principles and the study was approved by the Clinical Research Ethics Committee of Peking University First Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}